Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Pharm Sci ; 106(5): 1211-1217, 2017 05.
Article in English | MEDLINE | ID: mdl-28137697

ABSTRACT

The viscosity of concentrated aqueous solutions of 3 clinical monoclonal antibodies (mAbs), Erbitux®, Herceptin®, and Rituxan®, has been reduced up to over 10-fold by adding certain bulky polar additives instead of saline at isotonic levels. Because these additives are also found not to compromise mAbs' stability against aggregation induced by stresses, a drug-delivery modality switch from intravenous infusions to more convenient and inexpensive parenteral options like subcutaneous injections may become possible.


Subject(s)
Antibodies, Monoclonal/chemistry , Cetuximab/chemistry , Chemistry, Pharmaceutical/methods , Trastuzumab/chemistry , Antibodies, Monoclonal/metabolism , Cetuximab/metabolism , Chromatography, Gel/methods , Pharmaceutical Solutions/chemistry , Pharmaceutical Solutions/metabolism , Trastuzumab/metabolism , Viscosity
2.
Vaccine ; 33(25): 2930-8, 2015 Jun 09.
Article in English | MEDLINE | ID: mdl-25930118

ABSTRACT

Microstructure patches provide an opportunity for simple, effective, and safe vaccine administration, while achieving the desired immune response. We have evaluated the MicroCor transdermal system for cell culture-derived trivalent influenza vaccine administration. Influenza monovalent purified bulk vaccines (monobulks) (H1N1, H3N2, B) were concentrated by tangential flow filtration, lyophilized, and formulated with biocompatible excipients to form the microstructure array dissolvable tips. Standard single radial immunodiffusion (SRID) determined that the influenza antigens retained potency through the formulation and microstructure array fabrication processes. Array stability was evaluated for storage in both refrigerated and room temperature conditions. Microstructure mechanical strength was confirmed by application to excised pig skin, resulting in successful skin penetration and tip dissolution within 5 min of microstructure insertion. Guinea pigs immunized with influenza vaccine-loaded microstructures had hemagglutinin inhibition (HI) and IgG titers comparable to those obtained by intramuscular injection. After two immunizations, serum HI titers for all immunized groups were greater than 40 (>4-fold higher than the untreated group). These data demonstrate the feasibility for the development of skin delivery technologies that are compatible with cell culture-derived influenza vaccines.


Subject(s)
Influenza A Virus, H1N1 Subtype/immunology , Influenza A Virus, H3N2 Subtype/immunology , Influenza B virus/immunology , Influenza Vaccines/immunology , Administration, Cutaneous , Animals , Antibodies, Viral/blood , Antigens, Viral/blood , Antigens, Viral/immunology , Cells, Cultured , Female , Guinea Pigs , Hemagglutination Inhibition Tests , Hemagglutinin Glycoproteins, Influenza Virus/immunology , Humans , Immunodiffusion , Immunoglobulin G/blood , Influenza Vaccines/administration & dosage , Influenza, Human/prevention & control , Orthomyxoviridae Infections/prevention & control , Vaccination
3.
Vaccine ; 32(20): 2382-8, 2014 Apr 25.
Article in English | MEDLINE | ID: mdl-24434044

ABSTRACT

Influenza is a vaccine-preventable disease that remains a major health problem world-wide. Needle and syringe are still the primary delivery devices, and injection of liquid vaccine into the muscle is still the primary route of immunization. Vaccines could be more convenient and effective if they were delivered by the mucosal route. Elicitation of systemic and mucosal innate and adaptive immune responses, such as pathogen neutralizing antibodies (including mucosal IgA at the site of pathogen entry) and CD4(+) T-helper cells (especially the Th17 subset), have a critical role in vaccine-mediated protection. In the current study, a sublingual subunit influenza vaccine formulated with or without mucosal adjuvant was evaluated for systemic and mucosal immunogenicity and compared to intranasal and intramuscular vaccination. Sublingual administration of adjuvanted influenza vaccine elicited comparable antibody titers to those elicited by intramuscular immunization with conventional influenza vaccine. Furthermore, influenza-specific Th17 cells or neutralizing mucosal IgA were detected exclusively after mucosal immunization.


Subject(s)
Administration, Sublingual , Influenza Vaccines/administration & dosage , Orthomyxoviridae Infections/prevention & control , Th17 Cells/immunology , Vaccination/methods , Adjuvants, Immunologic/administration & dosage , Animals , Antibodies, Neutralizing/immunology , Antibodies, Viral/blood , Antibodies, Viral/immunology , Female , Hemagglutination Inhibition Tests , Humans , Immunity, Mucosal , Immunoglobulin A/immunology , Influenza A Virus, H1N1 Subtype , Injections, Intramuscular , Mice , Mice, Inbred BALB C , Vaccines, Subunit/administration & dosage
4.
J Pharm Sci ; 102(3): 866-75, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23303584

ABSTRACT

Vaccine antigens are usually available only as dilute solutions, which are difficult to formulate into various novel delivery systems, which often require highly concentrated antigens. To address this problem, we have utilized tangential flow filtration (TFF), a simple and scalable process to prepare highly concentrated vaccine antigens. Here, we describe the optimization of TFF to concentrate hemagglutinin (HA) of egg-derived influenza antigens, from 2008 to 2009 seasonal vaccine, to concentrations up to 28 mg/mL. Concentrated antigen was evaluated by single radial immunodiffusion and reversed-phase high-performance liquid chromatographic analysis for the estimation of the HA content and a range of assays including size exclusion, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and bicinchoninic acid assay for protein characterization. In addition, the concentrated antigens retained their immunogenicity, confirmed by the induction of immune responses comparable to that of unprocessed antigen in a mouse model. The liquid concentrates were stable for up to 4 weeks, which could allow subsequent formulation into novel delivery technologies. Hence, we have used influenza HA to demonstrate that the fast, robust, and scalable approach of TFF can be used to concentrate antigens for use in novel delivery approaches. Moreover, the concentration process could be applicable for a variety of antigens and a wide range of novel vaccine delivery applications.


Subject(s)
Antigens, Viral/administration & dosage , Antigens, Viral/isolation & purification , Hemagglutinin Glycoproteins, Influenza Virus/administration & dosage , Hemagglutinin Glycoproteins, Influenza Virus/isolation & purification , Influenza Vaccines/administration & dosage , Influenza Vaccines/isolation & purification , Orthomyxoviridae Infections/prevention & control , Animals , Antibody Formation , Antigens, Viral/immunology , Chromatography, Gel , Drug Delivery Systems , Electrophoresis, Polyacrylamide Gel , Female , Filtration/instrumentation , Hemagglutinin Glycoproteins, Influenza Virus/immunology , Humans , Influenza A Virus, H1N1 Subtype/immunology , Influenza A Virus, H3N2 Subtype/immunology , Influenza Vaccines/immunology , Influenza, Human/immunology , Influenza, Human/prevention & control , Mice , Mice, Inbred BALB C , Orthomyxoviridae Infections/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...